Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
levofloxacin + amoxicillin
- Development stage
- Unknown
- Lead developer
- Beijing Center for Disease Control and Prevention
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
levofloxacin + amoxicillin is a combination antibiotic regimen consisting of the fluoroquinolone levofloxacin and the beta-lactam amoxicillin. This dual-antibiotic protocol has been utilized as an active comparator in clinical trials, specifically for the treatment of uncomplicated recurrent urinary tract infections (rUTI). Levofloxacin acts by inhibiting bacterial DNA gyrase and topoisomerase IV, which are essential for DNA replication, transcription, and repair. Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis. The regimen typically involves levofloxacin 200 mg twice daily and amoxicillin 500 mg three times daily for one week.
- Other names
- levofloxacin and amoxicillin
02
Targets
DNA gyraseTopo IV (Bacterial Topoisomerase IV)PBP (Penicillin-binding protein family)
Beyond the preview
Go deeper on levofloxacin + amoxicillin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on levofloxacin + amoxicillin.